Martin M, Zielinski C, Ruiz-Borrego M, Carrasco E, et al. Overall survival with palbociclib plus endocrine therapy versus capecitabine in postmenopausal patients with hormone receptor-positive, HER2-negative metastatic breast cancer in the PEARL study. Eur J Cancer 2022;168:12-24.
PMID: 35429901